以手术为主的食管胃交界部腺癌综合治疗研究进展  

Progress of surgery-prioritized comprehensive therapy for adenocarcinoma of esophagogastric junction

作　　者：张国超 赵格非 薛奇 

机构地区：[1]国家癌症中心/中国医学科学院,北京协和医学院肿瘤医院胸外科,100021

出　　处：《肿瘤研究与临床》2017年第11期788-792,共5页Cancer Research and Clinic

基　　金：国家重点研发计划（2016YECl303200）

摘　　要：食管胃交界部腺癌（AEG）因其独特的解剖学位置及生物学特性,诊断分型及治疗模式始终没有公认的“金标准”.近年来,由于AEG发病率快速升高,其在公共健康问题中的重要性日益凸显.外科手术被认为是AEG的首选治疗方式,但不同类型AEG的手术方式尚存争议.许多临床试验已经证明术后辅助治疗或新辅助治疗对提高手术切除率及生存率有益,分子靶向药物可能为进展期AEG的治疗带来曙光.随着科学技术的发展和各项大型临床研究结果的公布,AEG的治疗日益个体化.文章针对以手术为主的AEG综合治疗的最新研究进展进行综述.The classification and treatment patterns of adenocarcinoma of esophagogastric junction （AEG）do not comply with the＂gold standard＂for its unique anatomical location and biological characteristics. With an increasing incidence rate of AEG in recent years, the importance of AEG in public health has caught much attention. Surgery is considered as the first choice for the treatment of AEG, but surgical treatments for different types of AEG is still controversial. Many clinical trials have proved the adjuvant therapy and neoadjuvant therapy are beneficial to the improvement of surgical resection and survival rate. Molecular targeted drugs might bring light for the treatment of advanced AEG. Individual therapy of AEG has become increasingly important with the development of science and technology and the results of large clinical researches published. This article reviews the latest progress of surgery-prioritized multimodality therapy for AEG.

关 键 词：食管肿瘤 胃肿瘤 腺癌 外科手术 综合治疗 新辅助治疗 

分 类 号：R735[医药卫生—肿瘤]